Autoimmune Addison disease is a rare autoimmune disorder with symptoms that typically develop over months or years. Following the development of serum autoantibodies to the key steroidogenic enzyme, 21-hydroxylase, patients have a period of compensated or preclinical disease, characterized by elevations in adrenocortocotropic hormone and renin, before overt, symptomatic adrenal failure develops. We propose that local failure of steroidogenesis, causing breakdown of tolerance to adrenal antigens, might be a key factor in disease progression. The etiology of autoimmune Addison disease has a strong genetic component in man, and several dog breeds are also susceptible. Allelic variants of genes encoding molecules of both the adaptive and innate immune systems have now been implicated, with a focus on the immunological synapse and downstream participants in T lymphocyte antigen-receptor signaling. With the exception of MHC alleles, which contribute to susceptibility in both human and canine Addison disease, no major or highly penetrant disease alleles have been found to date. Future research into autoimmune Addison disease, making use of genome-wide association studies and next-generation sequencing technology, will address the gaps in our understanding of the etiology of this disease.
Autoimmune Addison disease (AAD) is among the rarest of the autoimmune endocrinopathies
An aberrant immune response directed, at least in part, at the steroidogenic enzymes of the adrenal cortex (in particular 21-hydroxylase) underlies most cases of AAD
The progression of AAD can be slow, with an insidious decline into adrenal failure over months and years
Circumstantial evidence suggests that the glucocorticoid-rich adrenal milieu might give natural protection to adrenal antigens from the immune system
AAD has a strong genetic component, but owing to its rarity the recurrence rate in family members is of the order of 2%
Several disease-susceptibility alleles have been identified, including three loci associated with organ-specific autoimmunity (MHC, CTLA4 and PTPN22), and others that encode proteins involved in innate immune responses
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kong, M. F. & Jeffcoate, W. Eighty-six cases of Addison's disease. Clin. Endocrinol. (Oxf.) 41, 757–761 (1994).
Laureti, S., Vecchi, L., Santeusanio, F. & Falorni, A. Is the prevalence of Addison's disease underestimated? J. Clin. Endocrinol. Metab. 84, 1762 (1999).
Løvås, K. & Husebye, E. S. High prevalence and increasing incidence of Addison's disease in western Norway. Clin. Endocrinol. (Oxf.) 56, 787–791 (2002).
Addison, T. On The Constitutional And Local Effects Of Disease Of The Supra-Renal Capsules (1855).
Ten, S., New, M. & Maclaren, N. Clinical review 130: Addison's disease 2001. J. Clin. Endocrinol. Metab. 86, 2909–2922 (2001).
Nerup, J. Addison's disease—a review of some clinical, pathological and immunological features. Dan Med. Bull. 21, 201–217 (1974).
Söderbergh, A. et al. Adrenal autoantibodies and organ-specific autoimmunity in patients with Addison's disease. Clin. Endocrinol. (Oxf.) 45, 453–460 (1996).
Zelissen, P. M., Bast, E. J. & Croughs, R. J. Associated autoimmunity in Addison's disease. J. Autoimmun. 8, 121–130 (1995).
Lander, E. S. & Schork, N. J. Genetic dissection of complex traits. Science 265, 2037–2048 (1994).
Winqvist, O., Karlsson, F. A. & Kampe, O. 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet 339, 1559–1562 (1992).
Nikoshkov, A. et al. A conformation-dependent epitope in Addison's disease and other endocrinological autoimmune diseases maps to a carboxyl-terminal functional domain of human steroid 21-hydroxylase. J. Immunol. 162, 2422–2426 (1999).
Nikfarjam, L. et al. Mechanism of inhibition of cytochrome P450 C21 enzyme activity by autoantibodies from patients with Addison's disease. Eur. J. Endocrinol. 152, 95–101 (2005).
Furmaniak, J. et al. Autoimmune Addison's disease—evidence for a role of steroid 21-hydroxylase autoantibodies in adrenal insufficiency. J. Clin. Endocrinol. Metab. 79, 1517–1521 (1994).
Boscaro, M. et al. Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo. J. Clin. Endocrinol. Metab. 81, 2801–2804 (1996).
Krohn, K., Uibo, R., Aavik, E., Peterson, P. & Savilahti, K. Identification by molecular cloning of an autoantigen associated with Addison's disease as steroid 17 alpha-hydroxylase. Lancet 339, 770–773 (1992).
Winqvist, O., Gustafsson, J., Rorsman, F., Karlsson, F. A. & Kampe, O. Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type I and Addison's disease. J. Clin. Invest. 92, 2377–2385 (1993).
Betterle, C. et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J. Endocrinol. 117, 467–475 (1988).
Coco, G. et al. Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies. J. Clin. Endocrinol. Metab. 91, 1637–1645 (2006).
Torrejón, S., Webb, S. M., Rodriguez-Espinosa, J., Martinez de Osaba, M. J. & Corcoy, R. Long-lasting subclinical Addison's disease. Exp. Clin. Endocrinol. Diabetes 115, 530–532 (2007).
Smans, L. C. & Zelissen, P. M. Partial recovery of adrenal function in a patient with autoimmune Addison's disease. J. Endocrinol. Invest. 31, 672–674 (2008).
De Bellis, A. et al. Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. J. Clin. Endocrinol. Metab. 76, 1002–1007 (1993).
De Bellis, A. A. et al. Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report. J. Clin. Endocrinol. Metab. 86, 675–678 (2001).
Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat. Genet. 17, 399–403 (1997).
Nagamine, K. et al. Positional cloning of the APECED gene. Nat. Genet. 17, 393–398 (1997).
Pearce, S. H. et al. A common and recurrent 13-bp deletion in the autoimmune regulator gene in British kindreds with autoimmune polyendocrinopathy type 1. Am. J. Hum. Genet. 63, 1675–1684 (1998).
Pearce, S. H. & Cheetham, T. D. Autoimmune polyendocrinopathy syndrome type 1: treat with kid gloves. Clin. Endocrinol. (Oxf.) 54, 433–435 (2001).
Zlotogora, J. & Shapiro, M. S. Polyglandular autoimmune syndrome type I among Iranian Jews. J. Med. Genet. 29, 824–826 (1992).
Rosatelli, M. C. et al. A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. Hum. Genet. 103, 428–434 (1998).
Perheentupa, J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J. Clin. Endocrinol. Metab. 91, 2843–2850 (2006).
Wolff, A. S. et al. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J. Clin. Endocrinol. Metab. 92, 595–603 (2007).
Neufeld, M., Maclaren, N. K. & Blizzard, R. M. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 60, 355–362 (1981).
Ahonen, P., Myllarniemi, S., Sipila, I. & Perheentupa, J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N. Engl. J. Med. 322, 1829–1836 (1990).
Betterle, C., Greggio, N. A. & Volpato, M. Clinical review 93: Autoimmune polyglandular syndrome type 1. J. Clin. Endocrinol. Metab. 83, 1049–1055 (1998).
Akirav, E. M., Ruddle, N. H. & Herold, K. C. The role of AIRE in human autoimmune disease. Nat. Rev. Endocrinol. 7, 25–33 (2011).
Betterle, C., Volpato, M., Greggio, A. N. & Presotto, F. Type 2 polyglandular autoimmune disease (Schmidt's syndrome). J. Pediatr. Endocrinol. Metab. 9 (Suppl. 1), 113–123 (1996).
Dittmar, M. & Kahaly, G. J. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J. Clin. Endocrinol. Metab. 88, 2983–2992 (2003).
Myhre, A. G. et al. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J. Clin. Endocrinol. Metab. 87, 618–623 (2002).
Drexhage, H. A. Autoimmune endocrinopathies (ed. Volpe, R.) 309–336 (Humana Press, 1999).
Greco, D. S. Hypoadrenocorticism in small animals. Clin. Tech. Small Anim. Pract. 22, 32–35 (2007).
Peterson, M. E., Kintzer, P. P. & Kass, P. H. Pretreatment clinical and laboratory findings in dogs with hypoadrenocorticism: 225 cases (1979–1993). J. Am. Vet. Med. Assoc. 208, 85–91 (1996).
Famula, T. R., Belanger, J. M. & Oberbauer, A. M. Heritability and complex segregation analysis of hypoadrenocorticism in the standard poodle. J. Small Anim. Pract 44, 8–12 (2003).
Oberbauer, A. M. et al. Inheritance of hypoadrenocorticism in bearded collies. Am. J. Vet. Res. 63, 643–647 (2002).
Pedersen, N. C. A review of immunologic diseases of the dog. Vet. Immunol. Immunopathol. 69, 251–342 (1999).
Smallwood, L. J. & Barsanti, J. A. Hypoadrenocorticism in a family of leonbergers. J. Am. Anim. Hosp. Assoc. 31, 301–305 (1995).
Chase, K., Sargan, D., Miller, K., Ostrander, E. A. & Lark, K. G. Understanding the genetics of autoimmune disease: two loci that regulate late onset Addison's disease in Portuguese Water Dogs. Int. J. Immunogenet. 33, 179–184 (2006).
Hughes, A. M., Jokinen, P., Bannasch, D. L., Lohi, H. & Oberbauer, A. M. Association of a dog leukocyte antigen class II haplotype with hypoadrenocorticism in Nova Scotia Duck Tolling Retrievers. Tissue Antigens 75, 684–690 (2010).
Bowen, D., Schaer, M. & Riley, W. Autoimmune polyglandular syndrome in a dog: a case report. J. Am. Anim. Hosp. Assoc. 22, 649–654 (1985).
Heggarty, H. Addison's disease in identical twins. Br. Med. J. 1, 559 (1968).
Simmonds, J. P. & Lister, J. Auto-immune Addison's disease in identical twins. Postgrad. Med. J. 54, 552–554 (1978).
Smith, M. E., Gough, J. & Galpin, O. P. Addison's disease in identical twins. Br. Med. J. 2, 1316 (1963).
Russell, G. A., Coulter, J. B., Isherwood, D. M., Diver, M. J. & Smith, D. S. Autoimmune Addison's disease and thyrotoxic thyroiditis presenting as encephalopathy in twins. Arch. Dis. Child. 66, 350–352 (1991).
Fairchild, R. S., Schimke, R. N. & Abdou, N. I. Immunoregulation abnormalities in familial Addison's disease. J. Clin. Endocrinol. Metab. 51, 1074–1077 (1980).
Hewitt, P. H. Addison's disease occurring in sisters. Br. Med. J. 2, 1530–1531 (1957).
Vyse, T. J. & Todd, J. A. Genetic analysis of autoimmune disease. Cell 85, 311–318 (1996).
Risch, N. Assessing the role of HLA-linked and unlinked determinants of disease. Am. J. Hum. Genet. 40, 1–14 (1987).
Vaidya, B., Kendall-Taylor, P. & Pearce, S. H. The genetics of autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 87, 5385–5397 (2002).
Hemminki, K., Li, X., Sundquist, J. & Sundquist, K. Familial association between type 1 diabetes and other autoimmune and related diseases. Diabetologia 52, 1820–1828 (2009).
Maclaren, N. K. & Riley, W. J. Inherited susceptibility to autoimmune Addison's disease is linked to human leukocyte antigens-DR3 and/or DR4, except when associated with type I autoimmune polyglandular syndrome. J. Clin. Endocrinol. Metab. 62, 455–459 (1986).
Boehm, B. O. et al. The HLA-DQ beta non-Asp-57 allele: a predictor of future insulin-dependent diabetes mellitus in patients with autoimmune Addison's disease. Tissue Antigens 37, 130–132 (1991).
Huang, W. et al. Although DR3-DQB1*0201 may be associated with multiple component diseases of the autoimmune polyglandular syndromes, the human leukocyte antigen DR4-DQB1*0302 haplotype is implicated only in beta-cell autoimmunity. J. Clin. Endocrinol. Metab. 81, 2559–2563 (1996).
Partanen, J., Peterson, P., Westman, P., Aranko, S. & Krohn, K. Major histocompatibility complex class II and III in Addison's disease MHC alleles do not predict autoantibody specificity and 21-hydroxylase gene polymorphism has no independent role in disease susceptibility. Hum. Immunol. 41, 135–140 (1994).
Park, Y. S. et al. Additional association of intra-MHC genes, MICA and D6S273, with Addison's disease. Tissue Antigens 60, 155–163 (2002).
Yu, L. et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J. Clin. Endocrinol. Metab. 84, 328–335 (1999).
Peterson, P. et al. Steroid 21-hydroxylase gene polymorphism in Addison's disease patients. Tissue Antigens 46, 63–67 (1995).
Gambelunghe, G. et al. Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease. J. Clin. Endocrinol. Metab. 84, 3701–3707 (1999).
Triolo, T. M. et al. Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 94, 4517–4523 (2009).
Dziembowska, M. et al. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency. Immunogenetics 53, 821–829 (2002).
Koizumi, K. et al. Single nucleotide polymorphisms in the gene encoding the major histocompatibility complex class II transactivator (CIITA) in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 947–950 (2005).
Eyre, S. et al. Investigation of the MHC2TA gene, associated with rheumatoid arthritis in a Swedish population, in a UK rheumatoid arthritis cohort. Arthritis Rheum. 54, 3417–3422 (2006).
Ghaderi, M. et al. MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. J. Clin. Endocrinol. Metab. 91, 4107–4111 (2006).
Skinningsrud, B. et al. Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 93, 3310–3317 (2008).
Brunet, J. F. et al. A new member of the immunoglobulin superfamily--CTLA-4. Nature 328, 267–270 (1987).
Akamizu, T. et al. Association of autoimmune thyroid disease with microsatellite markers for the thyrotropin receptor gene and CTLA-4 in Japanese patients. Thyroid 10, 851–858 (2000).
Kotsa, K., Watson, P. F. & Weetman, A. P. A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. Clin. Endocrinol. (Oxf.) 46, 551–554 (1997).
Sale, M. M. et al. Association of autoimmune thyroid disease with a microsatellite marker for the thyrotropin receptor gene and CTLA-4 in a Japanese population. Proc. Assoc. Am. Physicians 109, 453–461 (1997).
Yanagawa, T., Hidaka, Y., Guimaraes, V., Soliman, M. & DeGroot, L. J. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J. Clin. Endocrinol. Metab. 80, 41–45 (1995).
Marron, M. P. et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum. Mol. Genet. 6, 1275–1282 (1997).
Nistico, L. et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum. Mol. Genet. 5, 1075–1080 (1996).
Seidl, C. et al. CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens 51, 62–66 (1998).
Vaidya, B. et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology (Oxford) 41, 180–183 (2002).
Vaidya, B. et al. Association analysis of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and autoimmune regulator-1 (AIRE-1) genes in sporadic autoimmune Addison's disease. J. Clin. Endocrinol. Metab. 85, 688–691 (2000).
Kemp, E. H. et al. A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison's disease in English patients. Clin. Endocrinol. (Oxf.) 49, 609–613 (1998).
Blomhoff, A. et al. Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease. J. Clin. Endocrinol. Metab. 89, 3474–3476 (2004).
Gerold, K. D. et al. The soluble ctla-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. Diabetes 60, 1955–1963 (2011).
Ueda, H. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506–511 (2003).
Daroszewski, J. et al. Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. Eur. J. Endocrinol. 161, 787–793 (2009).
Oaks, M. K. & Hallett, K. M. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J. Immunol. 164, 5015–5018 (2000).
Begovich, A. B. et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75, 330–337 (2004).
Kahles, H. et al. Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population. Eur. J. Endocrinol. 153, 895–899 (2005).
Velaga, M. R. et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J. Clin. Endocrinol. Metab. 89, 5862–5865 (2004).
Skinningsrud, B. et al. Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. Eur. J. Hum. Genet. 16, 977–982 (2008).
Roycroft, M. et al. The tryptophan 620 allele of the lymphoid tyrosine phosphatase (PTPN22) gene predisposes to autoimmune Addison's disease. Clin. Endocrinol. (Oxf.) 70, 358–362 (2009).
Vang, T. et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37, 1317–1319 (2005).
Rieck, M. et al. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J. Immunol. 179, 4704–4710 (2007).
Arechiga, A. F. et al. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J. Immunol. 182, 3343–3347 (2009).
Zhang, J. et al.The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat. Genet. 43, 902–907 (2011).
Brown, J. A. et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170, 1257–1266 (2003).
Hayashi, M., Kouki, T., Takasu, N., Sunagawa, S. & Komiya, I. Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients. Eur. J. Endocrinol. 158, 817–822 (2008).
Mitchell, A. L. et al. Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison's disease and Graves' disease susceptibility. J. Clin. Endocrinol. Metab. 94, 5139–5145 (2009).
Capon, F. et al. Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J. Invest. Dermatol. 116, 728–730 (2001).
Kochi, Y. et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat. Genet. 37, 478–485 (2005).
Kyogoku, C. et al. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. 46, 1242–1254 (2002).
Ehrhardt, G. R. et al. Fc receptor-like proteins (FCRL): immunomodulators of B cell function. Adv. Exp. Med. Biol. 596, 155–162 (2007).
Owen, C. J. et al. Analysis of the Fc receptor-like-3 (FCRL3) locus in Caucasians with autoimmune disorders suggests a complex pattern of disease association. J. Clin. Endocrinol. Metab. 92, 1106–1111 (2007).
Cummings, J. R. et al. The genetics of NOD-like receptors in Crohn's disease. Tissue Antigens 76, 48–56 (2010).
Jin, Y., Birlea, S. A., Fain, P. R. & Spritz, R. A. Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J. Invest. Dermatol. 127, 2558–2562 (2007).
Magitta, N. F. et al. A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes Immun. 10, 120–124 (2009).
Zurawek, M. et al. A coding variant in NLRP1 is associated with autoimmune Addison's disease. Hum. Immunol. 71, 530–534 (2010).
Hakonarson, H. et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 448, 591–594 (2007).
Zoledziewska, M. et al. Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. Genes Immun. 10, 15–17 (2009).
Dubois, P. C. et al. Multiple common variants for celiac disease influencing immune gene expression. Nat. Genet. 42, 295–302 (2010).
Marquez, A. et al. Specific association of a CLEC16A/KIAA0350 polymorphism with NOD2/CARD15− Crohn's disease patients. Eur. J. Hum. Genet. 17, 1304–1308 (2009).
Skinningsrud, B. et al. A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-CCP negative rheumatoid arthritis. Ann. Rheum. Dis. 69, 1471–1474 (2009).
Todd, J. A. et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 39, 857–864 (2007).
Mathieu, C., Waer, M., Laureys, J., Rutgeerts, O. & Bouillon, R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 37, 552–558 (1994).
Zella, J. B. & DeLuca, H. F. Vitamin D and autoimmune diabetes. J. Cell Biochem. 88, 216–222 (2003).
Pani, M. A. et al. A polymorphism within the vitamin D-binding protein gene is associated with Graves' disease but not with Hashimoto's thyroiditis. J. Clin. Endocrinol. Metab. 87, 2564–2567 (2002).
Lopez, E. R. et al. A promoter polymorphism of the CYP27B1 gene is associated with Addison's disease, Hashimoto's thyroiditis, Graves' disease and type 1 diabetes mellitus in Germans. Eur. J. Endocrinol. 151, 193–197 (2004).
Jennings, C. E., Owen, C. J., Wilson, V. & Pearce, S. H. A haplotype of the CYP27B1 promoter is associated with autoimmune Addison's disease but not with Graves' disease in a UK population. J. Mol. Endocrinol. 34, 859–863 (2005).
Betterle, C., Dal Pra, C., Mantero, F. & Zanchetta, R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr. Rev. 23, 327–364 (2002).
Dickerman, Z., Grant, D. R., Faiman, C. & Winter, J. S. Intraadrenal steroid concentrations in man: zonal differences and developmental changes. J. Clin. Endocrinol. Metab. 59, 1031–1036 (1984).
Rozkova, D., Horvath, R., Bartunkova, J. & Spisek, R. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin. Immunol. 120, 260–271 (2006).
Franchimont, D. et al. Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J. Immunol. 164, 1768–1774 (2000).
Abe, M. & Thomson, A. W. Dexamethasone preferentially suppresses plasmacytoid dendritic cell differentiation and enhances their apoptotic death. Clin. Immunol. 118, 300–306 (2006).
Cidlowski, J. A. et al. The biochemistry and molecular biology of glucocorticoid-induced apoptosis in the immune system. Recent Prog. Horm. Res. 51, 457–490; discussion 490–491 (1996).
Moser, M. et al. Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. Eur. J. Immunol. 25, 2818–2824 (1995).
Zubiaga, A. M., Munoz, E. & Huber, B. T. IL-4 and IL-2 selectively rescue Th cell subsets from glucocorticoid-induced apoptosis. J. Immunol. 149, 107–112 (1992).
Hayashi, Y., Hiyoshi, T., Takemura, T., Kurashima, C. & Hirokawa, K. Focal lymphocytic infiltration in the adrenal cortex of the elderly: immunohistological analysis of infiltrating lymphocytes. Clin. Exp. Immunol. 77, 101–105 (1989).
Vergeer, M. et al. Genetic variant of the scavenger receptor BI in humans. N. Engl. J. Med. 364, 136–145 (2011).
Metherell, L. et al. Mutations in GPX1 and NNT, endcoding antioxidant defense genes, cause familial glucocorticoid deficiency [Abstract]. Endocr. Rev. 32 (meeting abstracts), OR22–25 (2011).
Gombos, Z. et al. Analysis of extended human leukocyte antigen haplotype association with Addison's disease in three populations. Eur. J. Endocrinol. 157, 757–761 (2007).
Skinningsrud, B. et al. Multiple loci in the HLA complex are associated with Addison's disease. J. Clin. Endocrinol. Metab. 96, E1703–E1708 (2011).
Pani, M. A., Seissler, J., Usadel, K. H. & Badenhoop, K. Vitamin D receptor genotype is associated with Addison's disease. Eur. J. Endocrinol. 147, 635–640 (2002).
A. L. Mitchell is in receipt of a clinical research training fellowship from the Medical Research Council, UK. S. H. S Pearce's research work is supported by European Union Framework 7 grant 201167 to the Euradrenal Consortium and grants G07017632 & G0900001 from the Medical Research Council, UK. A. L. Mitchell and S. H. S. Pearce thank their collaborator, Professor Eystein Husebye, Dr Martina Ericksen and the group at Haukeland University Hospital, Bergen, Norway, for contributing family data on Addison disease gathered from the Norwegian registry of organ-specific autoimmune diseases for this Review.
The authors declare no competing financial interests.
About this article
Cite this article
Mitchell, A., Pearce, S. Autoimmune Addison disease: pathophysiology and genetic complexity. Nat Rev Endocrinol 8, 306–316 (2012). https://doi.org/10.1038/nrendo.2011.245
Nature Reviews Disease Primers (2021)
BMC Genomics (2020)
DLA class II risk haplotypes for autoimmune diseases in the bearded collie offer insight to autoimmunity signatures across dog breeds
Canine Genetics and Epidemiology (2019)
DLA class II haplotypes show sex-specific associations with primary hypoadrenocorticism in Standard Poodle dogs
Common genetic variation in the autoimmune regulator (AIRE) locus is associated with autoimmune Addison’s disease in Sweden
Scientific Reports (2018)